Activity

Activity ID

8262

Expires

June 4, 2024

Format Type

Journal-based

CME Credit

1

Fee

$30

CME Provider: JAMA Oncology

Description of CME Course

Patients with cancer are at risk for immune dysregulation related to underlying malignant disease as well as receipt of immunomodulatory cancer therapy. A notable concern is that patients with cancer may not mount a robust protective immune response to SARS-CoV-2 infection or vaccination. This risk seems most pronounced in patients with hematologic cancers: in a study of 167 patients with chronic lymphocytic leukemia in Israel who had received both doses of the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) for COVID-19, only 39.5% had a positive antibody response, and this proportion was even lower (16%) among patients on active treatment. Patients with solid malignant neoplasms may have a more preserved immune responseof 261 patients with cancer in New York City who had tested positive for SARS-CoV-2, the rate of seroconversion was 94.5% for those with solid tumors compared with 81.7% with hematologic cancers.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Oncology, Vaccination, Coronavirus (COVID-19)

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamaoncol.2021.2096

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.